Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 LMAT | Healthcare | $78.29 | 200.05K | $1.81B | 27.84 | 1.22% | Moderate Buy |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| LMAT | Lemaitre Vascular | 78.29 | -11.18 | -12.50% |
| Name | Price | % Change | |
|---|---|---|---|
| LMAT | $78.29 | -12.50% |
Lemaitre Vascular (($LMAT)) has held its Q3 earnings call. Read on for the main highlights of the call. LeMaitre Vascular delivered a broadly positive third-quarter earnings call, led by 12%
Barrington lowered the firm’s price target on LeMaitre (LMAT) to $91 from $95 and keeps an Outperform rating on the shares. While the firm doubts “investors will be thrilled with
Stifel analyst Rick Wise lowered the firm’s price target on LeMaitre (LMAT) to $105 from $120 and keeps a Buy rating on the shares. Published first on TheFly – the
Wells Fargo lowered the firm’s price target on LeMaitre (LMAT) to $86 from $94 and keeps an Equal Weight rating on the shares. The firm notes the company reported a
Citizens lowered the firm’s price target on LeMaitre (LMAT) to $110 from $127 and keeps an Outperform rating on the shares. LeMaitre’s Q3 results reflected roughly in-line quarterly sales and
Sees Q4 revenue $69.9M-$71.9M, consensus $72.24M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >>
Sees Q revenue $274.8M-$276.8M, consensus $276.53M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >>
Reports Q3 revenue $68.0M, consensus $67.37M. Chairman and CEO George LeMaitre (LMAT) said, “We expect 2026 to be another year of healthy sales (+11%) and EPS growth (+18%). Biologics continue
Lemaitre Vascular (LMAT) is scheduled to report 3rd quarter earnings on 11/04/2026, after the market closes. Regarding Q3 estimates, Wall Street analysts expect Lemaitre Vascular to post earnings of $0.69
Lemaitre Vascular (($LMAT)) has held its Q2 earnings call. Read on for the main highlights of the call. LeMaitre Vascular’s latest earnings call struck a notably upbeat tone, with management
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| LMAT | buy | Reiterated | Nov 5, 2026 | |||
| LMAT | buy | Reiterated | Nov 5, 2026 | |||
| LMAT | buy | Reiterated | Nov 5, 2026 | |||
| LMAT | hold | Reiterated | Nov 5, 2026 | |||
| LMAT | hold | Reiterated | Nov 5, 2026 | |||
| LMAT | hold | Reiterated | Aug 14, 2026 | |||
| LMAT | buy | Reiterated | May 6, 2026 | |||
| LMAT | buy | Reiterated | May 6, 2026 | |||
| LMAT | buy | Reiterated | Feb 26, 2026 | |||
| LMAT | hold | Reiterated | Nov 7, 2025 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| LMAT | Feb 25, 2027TBA | $1.81B | $0.73 | $71.19M | 1.06 | 27.84 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
